Unique ID issued by UMIN | UMIN000035316 |
---|---|
Receipt number | R000040207 |
Scientific Title | A verification study of safety evaluation of excessive ingestion of the yeast materials in humans: a randomized, double-blind, placebo-controlled, parallel study. |
Date of disclosure of the study information | 2019/01/01 |
Last modified on | 2020/03/05 18:41:34 |
A verification study of safety evaluation of excessive ingestion of the yeast materials in humans: a randomized, double-blind, placebo-controlled, parallel study.
Safety evaluation of excess ingestion of the yeast in humans.
A verification study of safety evaluation of excessive ingestion of the yeast materials in humans: a randomized, double-blind, placebo-controlled, parallel study.
Safety evaluation of excess ingestion of the yeast in humans.
Japan |
Healthy adult
Adult |
Others
NO
Safety evaluation of more than 5 times amount ingestion of the recommended daily intake of the test food.
Safety
1. Physical examination
2. Urinalysis
3. Blood test
* Assess these tests at screening and examination before consumption, at 2 and 4 weeks after consumption and 2 weeks after consumption completed.
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
Food |
Intake of Food containing yeast extracts once a day for 4 weeks.
Intake of placebo without yeast extracts once a day for 4 weeks.
20 | years-old | <= |
65 | years-old | >= |
Male and Female
1)Males and females from 20 to 65 years of age.
2)Subjects who are deagnosed as eligible to participate in the study by the physician
1)A medical history of malignant tumor, heart failure or myocardial infarction.
2) Currently undergoing treatment for any of the following chronic diseases: atrial fibrillation, cardiac arrhythmia, liver failure, kidney failure, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
3) Subjects who currently taking medications (including herbal medicines)
4) Subjects who are allergic to medications and/or the test food related products.
5) Subjects who are pregnant, breast-feeding, or planning to become pregnant.
6) Subjects who are judged as ineligible to participate in the study by the physician.
30
1st name | |
Middle name | |
Last name | Atsushi Yamatsu |
Pharma Foods International Co., Ltd.
Research and Development Department
1-49 Goryo-Ohara, Nishikyo-ku, Kyoto
075-394-8605
a-yamatsu@pharmafoods.co.jp
1st name | |
Middle name | |
Last name | Utano Nakamura |
Pharma Foods International Co., Ltd.
Research and Development Department
1-49 Goryo-Ohara, Nishikyo-ku, Kyoto
075-394-8605
u-nakamura@pharmafoods.co.jp
Pharma Foods International Co., Ltd
None
Self funding
YES
19-PFI-001
Nihonbashi-egawa clinical research ethical review committee
2019 | Year | 01 | Month | 01 | Day |
Unpublished
Completed
2018 | Year | 11 | Month | 26 | Day |
2018 | Year | 12 | Month | 14 | Day |
2018 | Year | 12 | Month | 25 | Day |
2019 | Year | 03 | Month | 25 | Day |
2018 | Year | 12 | Month | 19 | Day |
2020 | Year | 03 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040207
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |